spacer
home > pmps > summer 2002 > developing custom adhesive systems for transdermal drug delivery products
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Developing Custom Adhesive Systems for Transdermal Drug Delivery Products

Pharmaceutical companies in search of unique pressure-sensitive adhesive systems for their transdermal drug delivery (TDD) products are turning to specialty adhesives manufacturers to carry out research and development, testing, materials qualification, manufacturing, quality and other product development tasks. Trends suggest that adhesives manufacturers are forming partnerships with pharmaceutical companies as part of the product development process that ultimately includes manufacturing adhesive products to the relevant pharmaceutical current Good Manufacturing Practices (cGMPs). This article also discusses the technological advances that are occurring in terms of types of transdermal patch, adhesive properties and specialised components in transdermal drug delivery systems (TDDS).

Transdermal Drug Delivery Systems

The use of TDDS continues to gain market acceptance as a selected method of drug administration. The success of products that deliver materials such as nicotine for smoking cessation, nitroglycerin for angina, oestradiol and testosterone for hormone replacement therapy, and oestrogen and progesterone for birth control has ensured that the TDDS market is a strong industry segment with many more drug actives being formulated for transdermal delivery methods.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Melinda Hopp, Director of Marketing at Adhesives Research, Inc. Melinda Hopp has served as Director of Marketing at Adhesives Research, Inc. for the past six years. She previously worked for Southern New England Telephone as Director of Business Development; Duracell, Inc. (a division of Gillette Company) as Director of Market Development; and Novo Laboratories USA (a former division of NovoNordisk, Denmark) as Director of Market Research.
She started her career as a Research Chemist with Lehn & Fink Products (then a division of Sterling Drug). She has a BA in Biology/Chemistry, an MA in Science and an MBA from Fairleigh Dickinson University in New Jersey, US.

spacer
Melinda Hopp
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement